Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment
© 2017 John Wiley & Sons Ltd..
Antiviral drug resistance hepatitis B virus (HBV) variants (HBV-DR) occur spontaneously in chronic hepatitis B (CHB) patients and after exposure to nucleos(t)ide analogues (NUCs). We determined the prevalence of HBV-DR variants among participants of the Hepatitis B Research Network (HBRN) Cohort Study conducted at 21 sites in the United States (US) and Canada. Samples obtained from 1342 CHB participants aged ≥18 years, and who were currently not receiving NUCs, were tested for HBV-DR variants by Sanger sequencing. In addition, next generation sequencing (NGS) was used to characterize HBV-DR variants from 66 participants with and 66 participants with no prior NUC exposure matched for HBV genotype and HBV DNA level. Half the participants were men, 75% Asian, 26% HBeAg positive. Primary HBV-DR variants were detected by Sanger sequencing in 16 (1.2%) participants: 2/142 (1.4%) with and 14/1200 (1.2%) without prior NUC exposure; only 1 of these 16 had a secondary variant. In total, 23 (1.7%) participants had secondary variants, including 1 with prior NUC experience. In the subset of 132 participants, NGS detected HBV-DR variants in a higher proportion of participants: primary variants in 18 (13.6%) (8 [12.1%] with, and 10 [15.2%] without prior NUC therapy) and secondary variants in 10 (7.6%) participants. Based on Sanger sequencing, prevalence of primary HBV-DR variants is low (1.2%) among adults with CHB in US/Canada. The similar low prevalence of HBV-DR variants in participants with and without NUC treatment suggests transmission of these variants is uncommon.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Journal of viral hepatitis - 24(2017), 11 vom: 24. Nov., Seite 1032-1042 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lok, A S [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.05.2018 Date Revised 16.08.2019 published: Print-Electronic GENBANK: DK082863, DK082864, DK082866, DK082867, DK082871, DK082872, DK082874, DK082919, DK082923, DK082927, DK082943, DK082944 Citation Status MEDLINE |
|---|
| doi: |
10.1111/jvh.12732 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM272615064 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM272615064 | ||
| 003 | DE-627 | ||
| 005 | 20231224235240.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jvh.12732 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0908.xml |
| 035 | |a (DE-627)NLM272615064 | ||
| 035 | |a (NLM)28581155 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lok, A S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.05.2018 | ||
| 500 | |a Date Revised 16.08.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a GENBANK: DK082863, DK082864, DK082866, DK082867, DK082871, DK082872, DK082874, DK082919, DK082923, DK082927, DK082943, DK082944 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2017 John Wiley & Sons Ltd. | ||
| 520 | |a Antiviral drug resistance hepatitis B virus (HBV) variants (HBV-DR) occur spontaneously in chronic hepatitis B (CHB) patients and after exposure to nucleos(t)ide analogues (NUCs). We determined the prevalence of HBV-DR variants among participants of the Hepatitis B Research Network (HBRN) Cohort Study conducted at 21 sites in the United States (US) and Canada. Samples obtained from 1342 CHB participants aged ≥18 years, and who were currently not receiving NUCs, were tested for HBV-DR variants by Sanger sequencing. In addition, next generation sequencing (NGS) was used to characterize HBV-DR variants from 66 participants with and 66 participants with no prior NUC exposure matched for HBV genotype and HBV DNA level. Half the participants were men, 75% Asian, 26% HBeAg positive. Primary HBV-DR variants were detected by Sanger sequencing in 16 (1.2%) participants: 2/142 (1.4%) with and 14/1200 (1.2%) without prior NUC exposure; only 1 of these 16 had a secondary variant. In total, 23 (1.7%) participants had secondary variants, including 1 with prior NUC experience. In the subset of 132 participants, NGS detected HBV-DR variants in a higher proportion of participants: primary variants in 18 (13.6%) (8 [12.1%] with, and 10 [15.2%] without prior NUC therapy) and secondary variants in 10 (7.6%) participants. Based on Sanger sequencing, prevalence of primary HBV-DR variants is low (1.2%) among adults with CHB in US/Canada. The similar low prevalence of HBV-DR variants in participants with and without NUC treatment suggests transmission of these variants is uncommon | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Sanger sequencing | |
| 650 | 4 | |a antiviral treatment | |
| 650 | 4 | |a hepatitis B virus | |
| 650 | 4 | |a next generation sequencing | |
| 650 | 4 | |a nucleos(t)ide analogues | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a DNA, Viral |2 NLM | |
| 700 | 1 | |a Ganova-Raeva, L |e verfasserin |4 aut | |
| 700 | 1 | |a Cloonan, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Punkova, L |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, H-H S |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, W M |e verfasserin |4 aut | |
| 700 | 1 | |a Ghany, M G |e verfasserin |4 aut | |
| 700 | 0 | |a Hepatitis B Research Network (HBRN) |e verfasserin |4 aut | |
| 700 | 1 | |a Lau, Daryl T-Y |e investigator |4 oth | |
| 700 | 1 | |a Chung, Raymond T |e investigator |4 oth | |
| 700 | 1 | |a Roberts, Lewis R |e investigator |4 oth | |
| 700 | 1 | |a Smith, Coleman I |e investigator |4 oth | |
| 700 | 1 | |a Di Bisceglie, Adrian M |e investigator |4 oth | |
| 700 | 1 | |a -Melman, Mauricio |e investigator |4 oth | |
| 700 | 1 | |a Janssen, L A |e investigator |4 oth | |
| 700 | 1 | |a Wong, David K |e investigator |4 oth | |
| 700 | 1 | |a Juan, Joshua |e investigator |4 oth | |
| 700 | 1 | |a Feld, Jordan |e investigator |4 oth | |
| 700 | 1 | |a Yim, Colina |e investigator |4 oth | |
| 700 | 1 | |a Heathcote, Jenny |e investigator |4 oth | |
| 700 | 1 | |a Perrillo, Robert |e investigator |4 oth | |
| 700 | 1 | |a Do, Son |e investigator |4 oth | |
| 700 | 1 | |a Han, Steven-Huy B |e investigator |4 oth | |
| 700 | 1 | |a Tran, Tram T |e investigator |4 oth | |
| 700 | 1 | |a Terrault, Norah A |e investigator |4 oth | |
| 700 | 1 | |a Khalili, Mandana |e investigator |4 oth | |
| 700 | 1 | |a Cooper, Stewart L |e investigator |4 oth | |
| 700 | 1 | |a Fontana, Robert J |e investigator |4 oth | |
| 700 | 1 | |a Tsai, Naoky |e investigator |4 oth | |
| 700 | 1 | |a Fried, Michael W |e investigator |4 oth | |
| 700 | 1 | |a Patel, Keyur |e investigator |4 oth | |
| 700 | 1 | |a Evon, Donna |e investigator |4 oth | |
| 700 | 1 | |a Carithers, Robert C |e investigator |4 oth | |
| 700 | 1 | |a Shuhart, Margaret |e investigator |4 oth | |
| 700 | 1 | |a Kowdley, Kris V |e investigator |4 oth | |
| 700 | 1 | |a Wang, Chia C |e investigator |4 oth | |
| 700 | 1 | |a Sterling, Richard K |e investigator |4 oth | |
| 700 | 1 | |a Jake Liang, T |e investigator |4 oth | |
| 700 | 1 | |a Hoofnagle, Jay H |e investigator |4 oth | |
| 700 | 1 | |a Doo, Edward |e investigator |4 oth | |
| 700 | 1 | |a Chang, Kyong-Mi |e investigator |4 oth | |
| 700 | 1 | |a Park, Jang-June |e investigator |4 oth | |
| 700 | 1 | |a Belle, Steven H |e investigator |4 oth | |
| 700 | 1 | |a Wahed, Abdus |e investigator |4 oth | |
| 700 | 1 | |a Kleiner, David |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of viral hepatitis |d 1997 |g 24(2017), 11 vom: 24. Nov., Seite 1032-1042 |w (DE-627)NLM074659642 |x 1365-2893 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2017 |g number:11 |g day:24 |g month:11 |g pages:1032-1042 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jvh.12732 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2017 |e 11 |b 24 |c 11 |h 1032-1042 | ||